Hatice Odabasi

34PUBLICATIONS
82CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Innate immunityMolecular targetsHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (34)

|Jun 26, 2026
Prognostic Significance of Preoperative PET-CT SUVmax in Resected Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.

|Mar 19, 2026
Outcomes of CDK4/6 Inhibitor-Based Therapy in Premenopausal HR+/HER2- Metastatic Breast Cancer: Real World Data From A Multicenter Study.

Hatice Odabaş, Omar Alomari, Seval Orman

|Mar 14, 2026
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim

|Feb 27, 2026
Association Between Body Mass Index and Clinical Outcomes of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study.

Seval Orman, Miray Aydoğan, Nisanur Sarıyar Busery

|Jan 28, 2026
Adjuvant Chemotherapy and Chemoradiotherapy in Gastric Cancer: Prognostic Determinants and Real-World Survival Outcomes.

Sedat Yildirim, Hatice Odabas, Seval Ay Ersoy

|Jan 28, 2026
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study.

Ugur Ozkerim, Oguzcan Kinikoglu, Sila Oksuz

Pageof 6

Frequent Collaborators

24 joint publications

Nedim Turan

23 joint publications

Deniz Işık

22 joint publications

Oğuzcan Kınıkoğlu

20 joint publications

Sedat Yıldırım